HTRA1 Specific Neutra™ Antibody Products

Product list

High-temperature requirement A serine peptidase 1 (HTRA1) belongs to the HtrA family of serine proteases and plays a part in several biological processes. HTRA1 is typically secreted into the extracellular space and can also be found in various tissues and body fluids. Structurally, HTRA1 consists of a trimeric arrangement of protease domains with a PDZ domain at the C-terminus. Functionally, HTRA1 plays a role in the regulation of extracellular matrix components, cell signaling pathways, and apoptosis. Additionally, HTRA1 has been recognized for its role in tissue remodeling and its potential as a biomarker and therapeutic target in various pathological conditions.

Its Gene ID: 5654, UniProtKB ID: Q92743, and OMIM ID: 602194.

HTRA1 Signaling Pathways

HTRA1 participates in several signaling pathways that regulate biological activities. HTRA1 has been implicated in modulating transforming growth factor-beta (TGFB) signaling by cleaving extracellular matrix components and regulating TGFB bioavailability. Additionally, HTRA1 has been linked to the regulation of Wnt signaling pathways, which are critical for cell proliferation and differentiation. Moreover, HTRA1 can interact with components of the Notch signaling pathway, influencing cell fate determination and tissue homeostasis. The complicated role of HTRA1 in these signaling pathways emphasizes its significance in a variety of physiological and pathological conditions.

Fig.1 Mechanisms for inactivating HTRA1. (Haffner, 2023) Fig.1 Mechanisms of HTRA1 inactivation.¹

HTRA1-Related Diseases and Pathology

In cancers, HTRA1's dysregulation has been observed in several malignancies, including breast, lung, ovarian, and pancreatic cancers. It has been linked to tumor progression, invasion, metastasis, and drug resistance, making it a potential prognostic biomarker and therapeutic target.

In cerebrovascular diseases, particularly in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), HTRA1 has been associated with vascular dysfunction and the pathogenesis of the disease.

Moreover, HTRA1's involvement extends to other conditions such as age-related macular degeneration (AMD), where genetic variations in the HTRA1 gene have been linked to an increased risk of developing AMD. In osteoarthritis, HTRA1 has been implicated in cartilage degradation and joint inflammation, suggesting a role in the disease's progression. Additionally, HTRA1 dysregulation has been reported in neurodegenerative disorders like Parkinson's disease and Alzheimer's disease, indicating its potential involvement in protein misfolding and aggregation processes.

Fig.2 HTRA1 in cancer cells. (Li, et al., 2020) Fig.2 Proposed role of HTRA1 in cancer cells.²

Antibody Targeting HTRA1

Advances in neutralizing antibodies targeting HTRA1 have shown promise in various disease contexts. These antibodies are designed to specifically bind and inhibit the activity of HTRA1, offering a potential therapeutic approach to modulate its effects on cellular processes. In the field of cancer research, neutralizing antibodies against HTRA1 may help in inhibiting tumor progression, metastasis, and drug resistance by blocking its proteolytic activity and downstream signaling pathways. In cerebrovascular diseases such as CADASIL, targeted neutralization of HTRA1 could mitigate vascular dysfunction and disease progression. Additionally, in conditions like AMD and osteoarthritis, neutralizing HTRA1 antibodies could potentially alleviate disease manifestations by regulating its pathological impact on tissue homeostasis.

Creative Biolabs offers almost thirty different types of anti-HTRA1 antibody products that are high-specificity and high uniformity and can be used for different applications.

REFERENCES

Haffner, Christof. "The emerging role of the HTRA1 protease in brain microvascular disease." Frontiers in Dementia 2 (2023): 1146055.
Li, Yihe, et al. "Molecular structure and the role of high‐temperature requirement protein 1 in skeletal disorders and cancers." Cell proliferation 53.2 (2020): e12746.

Show More Close